Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pharming Group has decided to widen its existing deal with Swedish Orphan Biovitrum (SOBI) to include new territories in the Balkans, North Africa and the Middle East to commercialize Ruconest (recombinant human C1 inhibitor) as a treatment for acute angioedema attacks in patients with hereditary angioedema (HAE).
Subscribe to our email newsletter
Following the signing of the expended deal, SOBI has placed an additional order for vials of Ruconest from Pharming.
The shipment forms part of SOBI’s preparation for the continued roll-out and intensified marketing of Ruconest across Europe.
The agreement allows Pharming to receive around EUR1.5m from SOBI for over a period of one year for these additional shipments under this order.
As per the terms of the distribution pact, SOBI has acquired finished product from Pharming for a transfer price that includes a sales related tiered royalty component.
Pharming CEO Sijmen de Vries said with this extension, patients in all EC territories, the Balkans, North Africa and the Middle East will soon be able to benefit from the efficacy and safety that Ruconest offers as the only recombinant enzyme replacement therapy for HAE.